We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: empagliflozin
MedXY News
EnglishTag

empagliflozin

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Empagliflozin Enhances Cardiovascular Protection in HFrEF Patients with Low Serum Magnesium: Evidence from EMPEROR-Reduced
CardiologyempagliflozinHFrEF

Empagliflozin Enhances Cardiovascular Protection in HFrEF Patients with Low Serum Magnesium: Evidence from EMPEROR-Reduced

By MedXY|Dec 26, 2025

This analysis of the EMPEROR-Reduced trial demonstrates that empagliflozin increases serum magnesium levels and provides a more pronounced reduction in cardiovascular events for patients with low baseline magnesium, revealing a novel electr

Comprehensive Review of the EMPEROR-Preserved Trial: Efficacy and Outcomes of Empagliflozin in Heart Failure with Preserved Ejection Fraction
Cardiologyempagliflozinheart failure with preserved ejection fraction

Comprehensive Review of the EMPEROR-Preserved Trial: Efficacy and Outcomes of Empagliflozin in Heart Failure with Preserved Ejection Fraction

By MedXY|Nov 28, 2025

This review comprehensively summarizes recent studies (2021–2024) from the EMPEROR-Preserved trial, highlighting empagliflozin’s consistent benefits on cardiovascular and renal outcomes, quality of life, and key clinical subgroups in HFpEF

Comprehensive Review of the EMPEROR-Preserved Trial: Efficacy and Safety of Empagliflozin in Heart Failure with Preserved Ejection Fraction
Cardiologyempagliflozinheart failure

Comprehensive Review of the EMPEROR-Preserved Trial: Efficacy and Safety of Empagliflozin in Heart Failure with Preserved Ejection Fraction

By MedXY|Nov 28, 2025

This review synthesizes the pivotal EMPEROR-Preserved Trial results, highlighting empagliflozin’s efficacy in reducing heart failure outcomes in patients with preserved ejection fraction.

Empagliflozin Protects the Kidney Across Clinical Spectra — Acute Dip Is Not a Dealbreaker
Diabetes & Endocrinologychronic kidney diseaseempagliflozin

Empagliflozin Protects the Kidney Across Clinical Spectra — Acute Dip Is Not a Dealbreaker

By MedXY|Nov 28, 2025

An individual participant-level meta-analysis of 23,340 participants shows empagliflozin reduces acute and chronic kidney events, slows eGFR decline, and lowers kidney failure risk regardless of predicted acute eGFR dip, diabetes, heart fai

Empagliflozin, Pioglitazone or Glimepiride as Third Agents with Metformin + DPP‑4 Inhibitor: Similar HbA1c Drops but Different Trade‑offs
Diabetes & Endocrinologyempagliflozintype 2 diabetes

Empagliflozin, Pioglitazone or Glimepiride as Third Agents with Metformin + DPP‑4 Inhibitor: Similar HbA1c Drops but Different Trade‑offs

By MedXY|Nov 17, 2025

A 24‑week randomized phase 4 trial found comparable HbA1c reductions when adding empagliflozin, pioglitazone or glimepiride to metformin plus a DPP‑4 inhibitor; metabolic and safety profiles differed, arguing for individualized third‑line s

Anaemia as a Predictor of Iron Dysregulation and Modulator of Empagliflozin Response in Heart Failure with Reduced Ejection Fraction: Insights from the EMPATROPISM-FE Trial
Cardiologyempagliflozinheart failure

Anaemia as a Predictor of Iron Dysregulation and Modulator of Empagliflozin Response in Heart Failure with Reduced Ejection Fraction: Insights from the EMPATROPISM-FE Trial

By MedXY|Oct 3, 2025

In patients with heart failure and reduced ejection fraction, anaemia predicts iron homeostasis disruption and influences response to empagliflozin, which increases myocardial iron and improves cardiac function and exercise capacity.

Empagliflozin’s Impact on Peripheral Microvascular Function in HFpEF: A Novel Vascular Insight
CardiologyempagliflozinHFpEF

Empagliflozin’s Impact on Peripheral Microvascular Function in HFpEF: A Novel Vascular Insight

By MedXY|Oct 2, 2025

Empagliflozin alters peripheral microvascular responses in HFpEF patients, enhancing insulin-mediated vasodilation but reducing acetylcholine responsiveness, suggesting a targeted vascular mechanism distinct from general endothelial or smoo

Exploring Combined Finerenone and Empagliflozin Therapy in CKD and Type 2 Diabetes: Baseline Insights from the CONFIDENCE Trial
Diabetes & Endocrinologychronic kidney diseaseclinical trial

Exploring Combined Finerenone and Empagliflozin Therapy in CKD and Type 2 Diabetes: Baseline Insights from the CONFIDENCE Trial

By MedXY|Oct 2, 2025

The CONFIDENCE trial evaluates whether combining finerenone with empagliflozin more effectively reduces urine albumin-to-creatinine ratio in CKD patients with type 2 diabetes compared to monotherapy, based on baseline characteristics of 818

Dual Renal Protection: Finerenone Plus Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes
Clinical Updateschronic kidney diseasediabetes

Dual Renal Protection: Finerenone Plus Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes

By MedXY|Oct 2, 2025

Combining finerenone with empagliflozin provides superior reduction in albuminuria for patients with chronic kidney disease and type 2 diabetes, without increased adverse events.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities